Selective up-regulation of the soluble pattern-recognition receptor pentraxin 3 and of vascular endothelial growth factor in giant cell arteritis: Relevance for recent optic nerve ischemia

Objective To assess local expression and plasma levels of pentraxin 3 (PTX3) in patients with giant cell arteritis (GCA). Methods Plasma and serum samples were obtained from 75 patients with GCA (20 of whom had experienced optic nerve ischemia in the previous 3 weeks and 24 of whom had experienced s...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis & rheumatology (Hoboken, N.J.) Vol. 64; no. 3; pp. 854 - 865
Main Authors: Baldini, Mattia, Maugeri, Norma, Ramirez, Giuseppe A., Giacomassi, Chiara, Castiglioni, Alessandra, Prieto-González, Sergio, Corbera-Bellalta, Marc, Comite, Gabriele Di, Papa, Ilenia, Dell'Antonio, Giacomo, Ammirati, Enrico, Cuccovillo, Ivan, Vecchio, Viviana, Mantovani, Alberto, Rovere-Querini, Patrizia, Sabbadini, Maria Grazia, Cid, Maria C., Manfredi, Angelo A.
Format: Journal Article
Language:English
Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01-03-2012
Wiley
Wiley Subscription Services, Inc
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective To assess local expression and plasma levels of pentraxin 3 (PTX3) in patients with giant cell arteritis (GCA). Methods Plasma and serum samples were obtained from 75 patients with GCA (20 of whom had experienced optic nerve ischemia in the previous 3 weeks and 24 of whom had experienced symptom onset in the previous 6 months and had no history of optic nerve ischemia) and 63 controls (35 age‐matched healthy subjects, 15 patients with rheumatoid arthritis, and 13 patients with chronic stable angina). In 9 patients in whom GCA was recently diagnosed, circulating levels of interleukin‐1β (IL‐1β), IL‐2, IL‐4, IL‐6, IL‐7, IL‐8, IL‐10, IL‐12p70, CCL2/monocyte chemotactic protein 1, CCL3/macrophage inflammatory protein 1α (MIP‐1α), CCL4/MIP‐1β, CCL11/eotaxin, CXCL9/monokine induced by interferon‐γ, CXCL10/interferon‐γ–inducible 10‐kd protein, tumor necrosis factor α (TNFα), interferon‐γ, vascular endothelial growth factor (VEGF), granulocyte–macrophage colony‐stimulating factor, and FasL were measured via a multiplexed cytometric assay. PTX3 and VEGF concentrations were assessed by enzyme‐linked immunosorbent assay. PTX3 and CD68 expression were determined by immunohistochemistry and immunofluorescence on temporal artery samples. Results GCA patients with very recent optic nerve ischemia had significantly higher PTX3 and VEGF levels compared to other GCA patients and controls. GCA patients with a disease duration of <6 months had significantly higher PTX3 levels compared to other GCA patients and controls. Immunohistochemistry revealed selective PTX3 expression in the wall of inflamed arteries. Conclusion Our findings indicate that local expression of PTX3 is a feature of vascular inflammation in GCA; elevated circulating levels of PTX3 identify patients with very recent optic nerve ischemia or a recent diagnosis. Optic nerve ischemia is also associated with increased circulating VEGF levels.
Bibliography:Associazione Italiana per la Ricerca sul Cancro
Ministero della Salute
Ministerio de Ciencia e Innovación - No. SAF 08/04328; No. SAF 11/30073
ArticleID:ART33411
ark:/67375/WNG-8L24GC7X-W
European Research Council
Marató TV3 Foundation - No. 06/0710
istex:400167FA11E19F498094BBA67E4E466665977A13
MIUR
Dr. Mantovani is a named inventor on patents for PTX3.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0004-3591
2326-5191
1529-0131
2326-5205
DOI:10.1002/art.33411